Document is current
Any future updates will be listed below
-
Authors
Garcia-Beltran, Cristina
Malpique, Rita
Andersen, Marianne S.
Bas, Firdevs
Bassols, Judit
Darendeliler, Feyza
Díaz, Marta
Dieris, Barbara
Fanelli, Flaminia
Fröhlich-Reiterer, Elke
Gambineri, Alessandra
Glintborg, Dorte
López-Bermejo, Abel
Mann, Christopher
Marin, Silvia
Obermayer-Pietsch, Barbara
Ødegård, Rønnaug
Ravn, Pernille
Reinehr, Thomas
Renzulli, Matteo
Salvador, Cristina
Singer, Viola
Vanky, Eszter
Torres, Juan Vicente
Yildiz, Melek
de Zegher, Francis
Ibáñez, Lourdes https://orcid.org/0000-0003-4595-7191
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (899671-SPIOMET4HEALTH)
- License Information
-
More Information
Article History
Received: 3 August 2023
Accepted: 17 August 2023
First Online: 15 September 2023
Declarations
:
: The study will be conducted in accordance with International Conference on Harmonisation Good Clinical Practice. The study has already obtained the full approval from all EC and National Competent Authorities. Written informed consent to participate will be obtained from participants or their parents (in case of minor participants).
: The model consent form and other related documentation given to participants will be provided on request.
: The universities of Barcelona and Leuven are joint holders of patents related to SPIOMET treatment of PCOS. The authors declare that they have no competing interests.
